COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
Perrine Vuagnat(Université de Versailles Saint-Quentin-en-Yvelines), François‐Clément Bidard(Inserm), Audrey Bellesœur(Hôpital Cochin), Jean‐Yves Pierga(Université Paris Cité), Vincent Servois(Université Paris Sciences et Lettres), Clémence Basse(Université de Versailles Saint-Quentin-en-Yvelines), Laurence Bozec(Institut Curie), Aurélien Noret(Institut Curie), Paul Cottu(Université Paris Sciences et Lettres), Enora Laas(Institut Curie), Maxime Frélaut(Institut Curie), Luc Cabel(Université de Versailles Saint-Quentin-en-Yvelines), Delphine Héquet(Institut Curie), Xavier Paolettí(Inserm), Toulsie Ramtohul(Université Paris Sciences et Lettres), Sarah Diakite(Institut Curie), Youlia Kirova(Institut Curie)
Cited by 18
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k